xoma.comXOMA – A biotech royalty aggregator

-- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- Skip to content Menu About Us Overview Management Team Board of Directors Contact Us Royalty Portfolio Opportunities Overview Royalty Acquisition Assets Available for Licensing Phage Display Platform IL-2 Antibody Anti-prolactin Antibody XMetA Portfolio Anti-PTH1R Antibody News Company & Partner News Press Releases Investors Overview News & Events Financial Information Stock Data Analyst Coverage SEC Filings Governance Contact Menu About Us Overview Management Team Board of Directors Contact Us Royalty Portfolio Opportunities Overview Royalty Acquisition Assets Available for Licensing Phage Display Platform IL-2 Antibody Anti-prolactin Antibody XMetA Portfolio Anti-PTH1R Antibody News Company & Partner News Press Releases Investors Overview News & Events Financial Information Stock Data Analyst Coverage SEC Filings Governance Contact We are a biotech royalty aggregator with 65+ assets and growing. XOMA plays a unique role in helping biotech companies achieve their goal of improving human health. We do this by acquiring the economic rights to future milestone and royalty payments associated with partnered pre-commercial clinical candidates. In return the seller receives non-dilutive, non-recourse funding to advance their internal drug candidate(s). LEARN MORE Royalty Portfolio We have an expansive portfolio of licenses that provides us the right to future potential royalty and milestone payments. The drug candidate assets underlying the licenses are being developed by others. learn more Royalty Acquisition We are actively acquiring the rights to future potential milestone and royalty payments to pre-commercial therapeutic assets being developed by pharmaceutical and biotech companies. learn more Investor Relations We use a portfolio approach to acquire new royalty assets, thereby mitigating single-asset binary exposure, and we operate under a capital-efficient structure to strive to deliver shareholder value. learn more Register for News Updates: Subscribe to our company news email list and receive XOMA news as it is released. To protect your privacy, your email address will be used only for this news distribution list. Leave this field empty if you’re human: February 2020 Download our latest presentation: DOWNLOAD NOW » Iscalimab Update December 5, 2019 See the latest Iscalimab update from the Novartis December R&D Day View PDF Latest News XOMA Announces Closing of Rights Offering December 20, 2019 Iscalimab (CFZ533) Update December 5, 2019 XOMA Announces Commencement of Rights Offering December 2, 2019 Terms of Use © 2019 XOMA Corporation. All rights reserved. Any references to “portfolio” on this website refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to “assets” on this website refer strictly to milestone and/or royalty rights associated with individual drug products in development. Follow us: © 2020 XOMA • Powered by GeneratePress Scroll back to top -- -- --...